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Abstract
Background:  Lopinavir/ritonavir (LPV/r) tablet compared to the soft gel capsule (SGC)
formulation has no oleic acid or sorbitol, has no refrigeration or food-restriction requirements, and
has less pharmacokinetic variability. We compared the tolerability, quality of life (QoL), and
formulation preference after switching from LPV/r SGC to the tablet formulation.
Methods: In a prospective, single-arm, cohort study-design, 74 human immunodeficiency virus
(HIV) infected subjects stable on LPV/r-based therapy were enrolled prior to (n = 25) or 8 weeks
(n = 49) after switching from SGC to tablet. Baseline data included clinical laboratory tests, bowel
habit survey (BHS) and QoL questionnaire (recalled if enrolled post-switch). Global Condition
Improvement (GCI)-score, BHS-score, QoL-score, and formulation preference data were captured
at weeks 4 and 12.
Results: At week 12 post-enrollment; the tablet was preferred to the SGC (74% vs. 10%, p <
0.0001). GCI-overall-tolerability score was 2.46 ± 3.30 on a scale of -7 to +7, with 90% admitting
to feeling better or about the same. Stool frequency, consistency, volume, and ± blood improved,
however the improvement was significant in "consistency" only (p = 0.03). Aggregate Bowel Habit-
Profile improved (BHS-score change = -0.227, p = 0.01). Inverse relationship existed between GCI
and BHS (slope = -1.2, p = 0.02) at week-4, suggesting that improved overall-tolerability was related
to better gastrointestinal (GI)-tolerance. QoL-scores were stable. Mean reductions in total
cholesterol of 9.20 mg/dL (p = 0.02), in triglycerides of 33 mg/dL (p = 0.04), and in HDL of 4.50
mg/dL (p = 0.01) unrelated to lipid-lowering therapy, were observed at week 12.
Conclusions: LPV/r-tablet was well tolerated and preferred to the SGC in HIV infected subjects,
with stable QoL and appreciable improvement in GI-tolerability. The unexpected changes in lipid
profile deserve further evaluation.
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Background
Lopinavir/ritonavir (LPV/r) tablet is now widely used in
combination with other antiretroviral agents in place of
the soft gel capsule (SGC) in the treatment of HIV-infec-
tion. Developed by the melt extrusion technology and
approved by the Food and Drug Administration in 2005
[1], LPV/r tablets have several advantages over the SGC.
The tablet allows a reduced pill burden (4 tablets/day vs.
6 SGC/day), is storable at room temperature, has no spe-
cial food requirement, and has comparable bioavailability
to the SGC and less plasma concentration variability [2,3].
Because the tablet formulation lacks oleic acid [1], an
excipient believed to contribute to gastrointestinal (GI)
intolerance in the SGC, it is expected for the tolerability of
LPV/r to improve with the tablet formulation.
In this report, the overall tolerability, GI-tolerance profile,
fasting lipid profile, quality of life (QoL), formulation
preference and satisfaction were prospectively evaluated
in a cohort of clinically stable HIV-infected subjects
treated with LPV/r based antiretroviral therapy who were
switched from the SGC to the tablet formulation. Because
of the advantages of the tablet over the SCG, we hypothe-
sized that the covariates evaluated, with the exception of
fasting lipid profile and QoL, would improve within 12
weeks of the switch.
Results
Patient demographics
Seventy-four clinically stable HIV-infected subjects were
enrolled, with 25 subjects (34%) switching from the SGC
to the LPV/r tablet formulation at entry and 49 subjects
(66%) having already switched to the tablet (within ≤8
weeks of enrollment). No patients withdrew from the
study prematurely. The subjects were predominantly Afri-
can American (74%) and males (82%). Detailed demo-
graphic characteristics are summarized in Table 1.
Formulation Preference and Satisfaction
At week 4 post-enrollment, a significantly greater propor-
tion of patients preferred LPV/r tablet to SGC formulation
(78% vs. 9%, p < 0.0001), and this pattern was main-
tained at week 12 (74% vs. 10%, p < 0.0001) (Table 2).
Medication satisfaction scores for LPV/r tablet were 9.01 ±
2.27 and 8.69 ± 2.25 at week 4 and 12 respectively on a
MSS (MSS) scale of 0 to12, where a higher number repre-
sents superior outcome.
Formulation Tolerability
The GCI-tolerability scores were 2.24 ± 3.05 at week 4 (p
< 0.0001) and 2.46 ± 3.30 at week 12, (p < 0.0001). Scores
were on a scale of -7 to +7 where a positive integer is an
indication of improved overall tolerability with the tablet
as compared to SGC (Table 2). Ninety percent of subjects
either "felt better" (45%) or "felt about the same" (45%),
with only 5% expressing feeling worse, while 5% did not
respond.
GI-tolerability
Overall change in daily bowel habit pattern was also
improved. Statistically significant changes in mean Bowel
Habit Score (BHS) score of -0.281 (p = 0.002) and -0.227
(p = 0.01) were observed at week 4 and week 12, respec-
tively. In the subset of subjects reporting changes in bowel
movement pattern, improvements were noted in all four
parameters assessed. However, only change in stool con-
Table 1: Subjects' Demographic Data at Study Entry
Study population (n = 74)
Male sex [No. (%)] 61 (82)
Race
African American [No. (%)] 55 (74)
White [No. (%)] 17 (23)
Hispanic [No. (%)] 2 (3)
†On LPV/r tablet at entry
No [No. (%)] 49 (66)
Yes [No. (%)] 25 (34)
On anti-diarrheal drug
No [No. (%)] 67 (92)
Yes [No. (%)] 6 (8)
On lipid lowering drug
No [No. (%)] 54 (74)
Yes [No. (%)] 19 (26)
Median age [years (IQR)] 43 (39-47)
Median weight [Kg (IQR)] 80.5 (69.60-88.60)
Median HIV-1 RNA [copies/ml (IQR)] 0.135 (0.05-0.70)
Median CD4 T-cell counts [cell/μl (IQR)] 294 (157-455)
LPV/r, lopinavir/ritonavir; SGC, soft gel capsule; IQR, inter-quartile range.AIDS Research and Therapy 2009, 6:29 http://www.aidsrestherapy.com/content/6/1/29
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sistency reached the level of statistical significance (Table
3). A decrease in stool frequency was reported by 18 of 28
subjects at week 4 (64%, p = 0.13), and by 18 of 32 sub-
jects at Week 12 (56%, p = 0.48). Stool consistency
improved in 23 of 30 subjects at week 4 (77%, p = 0.004),
and in 19 of 27 subjects at week 12 (70%, p = 0.03). A
reduction in stool volume occurred in 11 of 16 subjects at
week 4 (69%, p = 0.13), and in 8 of 13 subjects at week 12
(62%, p = 0.41). Resolution of blood in stool occurred in
5 of 6 subjects at week 4 (83%, p = 0.10), and in 4 of 6
subjects at week 12 (67%, p = 0.41).
Impact of GI-tolerability on overall formulation 
tolerability
To examine whether the change in Global Conditioning
Improvement-tolerability score was resultant of the
change in BHS-score, a simple linear regression was per-
formed. For every unit reduction in mean BHS-score from
baseline to week 4, the GCI-score at week 4 improved by
an average of 1.2 points (slope = -1.2, p = 0.02), however,
this effect seemed to diminish by week 12 (slope = -0.95,
p = 0.11).
QoL Assessment
The MOS-HIV health survey (Physical Health Summary
Score (PHS) and Mental Health Summary Score (MHS)),
Augmented Symptom Distress Module (ASDM), and
Center for Epidemiology Studies-Depression (CES-D)
instruments, which evaluated physical functioning, pain,
social functioning, emotional well-being, energy/fatigue,
health transition, and overall QoL, showed no differences
between the SGC and tablet formulations (Table 2).
Fasting lipid profile
In a subset of subjects not treated with lipid lowering
agents, mean changes of -9.2 mg/dl (n = 44, p = 0.02) in
Table 2: Quality of Life, Medication Satisfaction, and Tolerability Scores
Quality of life instruments Baseline Change from baseline to week 4 Change from baseline to week 12
Mean (SD) Mean (SD) P-value Mean (SD) P-value
*Physical health summary score (PHS) 48.2 (11.5) 0.015 ± 9.00 0.97 0.315 ± 9.20 0.79
*Mental health summary score (MHS) 50.7 (12.0) 0.366 ± 9.07 0.74 0.313 ± 10.01 0.81
*Augmented symptom distress module (ASDM) 26.7 (19.8) -2.99 ± 16.34 0.14 -2.92 ± 16.48 0.17
*Center for Epidemiology Studies-Depression 
(CES-D)
14.5 (10.2) -1.12 ± 8.00 0.25 -0.753 ± 8.47 0.49
Mean value at week 4 Mean value at week 12
Medication satisfaction survey (MSS) 9.01 ± 2.27 NA 8.69 ± 2.25 NA
Global Condition improvement (GCI) 2.24 ± 3.05 <0.0001 2.46 ± 3.30 <0.0001
Therapy preference
Prefer LPV/r tablet [No. (%)] 55 (78%) <0.0001 46 (74%) <0.0001
Prefer LPV/r SGC [No. (%)] 6 (9%) 6 (10%)
No preference [No. (%)] 9 (13%) 10 (16%)
*These instruments were scored according to the published scoring algorithm [4-6]; SD, standard deviation; SGC, soft gel capsule; LPV/r, lopinavir/
ritonavir;
Table 3: Bowel Habit Survey
Variables Baseline to week 4 Baseline to week 12
Improvement rate P-value Improvement rate P-value
Decrease in stool frequency among those reporting change 18/28 (64.3%) 0.13 18/32 (56.3%) 0.48
Improved stool consistency among those reporting change 23/30 (76.75%) 0.004 19/27 (70.4%) 0.03
Decrease in stool volume among those reporting change 11/16 (68.8%) 0.13 8/13 (61.5%) 0.41
Resolution of blood in stool among those reporting change 5/6 (83.3%) 0.10 4/6 (66.7%) 0.41
Baseline to week 4 (n = 70) Baseline to week 12 (n = 62)
Overall change in bowel habit score (BHS) [mean (SD)] -0.281 ± 0.719 0.002 -0.227 ± 0.707 0.01
Self-reported bowel habit score (BHS) was assessed on a scale in which stool consistency was (solid = 1, loose = 3, watery = 5); volume (small = 1, 
moderate = 3, large = 5), blood (no = 1, yes = 5); Frequency (1 - 5). For example, a subject with baseline responses of: Solid, Moderate, no blood, 
and frequency of "2" would have a score of: (1 + 3 + 1 + 2)/4 = 1.75 for their baseline summary score. Therefore the scale has a minimum of 1 (best 
BHS outcome) and a maximum of 5 (worst BHS outcome); SD, standard deviation.AIDS Research and Therapy 2009, 6:29 http://www.aidsrestherapy.com/content/6/1/29
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total cholesterol, -33.2 mg/dl (n = 38, p = 0.04) in triglyc-
eride, and -4.5 mg/dl (n = 37, p = 0.01) in HDL were
observed at week 12 (Table 4).
Discussion
LPV/r is a boosted protease inhibitor (PI) with potent
antiviral activity against wild-type and resistant HIV-
strains [4,5]. In clinical practice, it is extensively used in
treatment naïve and treatment experienced patients, and
it is a recommended first-line drug in treatment naïve
patients according to the Department of Human and
Health Services (DHHS) guidelines [6]. In its original for-
mulation, the SGC, the use of this drug was limited by its
high pill burden (6 capsules/day), the need for adminis-
tration in fed state to optimize bioavailability, refrigera-
tion storage requirement, and gastrointestinal intolerance
[3].
The meltrex-engineered LPV/r tablet was introduced to
overcome these shortcomings. The melt extrusion tech-
nology improves bioavailability of poorly soluble com-
pounds, such as LPV/r, by dissolving the drug in polymer
in a solvent-free environment. The drug remains in a state
of molecular dispersion as the polymer hardens. This
extruded material can then be shaped as tablets, granules,
pellets or powder which can be further processed into
conventional tablets [2]. The LPV/r tablet thus represents
an improvement over the SGC as it is stable at room tem-
perature, has a reduced daily pill count, and has no special
food requirement. The tablet formulation has been shown
to have comparable pharmacokinetic profile to the SGC
formulation with an added advantage of less inter-subject
plasma concentration variability [2]. Furthermore, Study
M05-730 demonstrated patients' preference for the tablet
after switching from the SGC [7].
The results of the current study confirm the overall tolera-
bility of the LPV/r tablet among HIV-infected subjects, its
improved GI-tolerability profile over the SGC, and a pref-
erence for its use among individuals who underwent a for-
mulation switch. Statistically significant improvements
were observed for all measures of medication satisfaction
at both the 4 and 12 week evaluation periods. Seventy-
eight percent and 74% of subjects preferred the tablet
LPV/r to the SGC at weeks 4 and 12, respectively. The Glo-
bal Condition improvement scale, a validated instrument
which ranks medication tolerability in terms of whether
subjects felt worse or better with a given drug, indicated an
improved overall tolerability following switch to the LPV/
r tablet. The week 4 GCI tolerability score was 2.24 ± 3.05
(p < 0.0001), while the week 12 GCI-score was 2.46 ± 3.30
(p < 0.0001) on a scale ranging from -7 to +7. The Medi-
cation Satisfaction Survey scores at week 4 of 9 ± 2.27 out
of 12 points (75%), and at week 12 of 8.69 ± 2.25 out of
12 points (72%) were consistent with the therapy prefer-
ence scores and further validate the overall preference of
the tablet over the SGC. The preference of the tablet over
the SGC is likely due to its reduced pill burden, lack of a
food requirement, and its ability to be stored at ambient
temperature.
GI-intolerance is commonly associated with PI therapy,
including LPV/r SGC [8,9]. It has been speculated that the
LPV/r tablet would have less GI side effects than the SGC,
because it lacks components that were present in the older
formulation (e.g., oleic acid) that may act as a laxative
[10]. Indeed, our results indicated an improved trend in
Table 4: Changes in Fasting Lipid Profile from Baseline to Week 12
Baseline Week 12 Baseline to week 12
Lipid Lowering Therapy Mean (SD) Mean (SD) Mean Change SD P-value
Total Cholesterol No (n = 44) 183 (36.6) 180 (35.4) -9.2 23.2 0.02
Yes (n = 18) 225 (64.3) 221 (55.1) -2.9 44.3 0.80
Total population 195 (49.7) 191 (45.1) -7.3 30.7 0.09
Triglycerides No (n = 38) 178 (114) 153 (105) -33.1 86.3 0.04
Yes (n = 16) 411 (392) 303 (281) -81.2 348.3 0.40
Total population 246 (253) 194 (182) -47.4 199.9 0.11
HDL No (n = 37) 45.3 (11.6) 44.6 (13.7) -4.5 9.4 0.01
Yes (n = 17) 36.1 (15.5) 39.1 (17.2) 1.7 9.5 0.49
Total population 42.4 (13.5) 43.0 (14.8) -2.5 9.8 0.88
LDL No (n = 38) 106 (28.0) 105 (25.9) -4.2 21.8 0.28
Yes (n = 16) 127 (54.9) 125 (36.1) 3.6 48.6 0.79
Total population 112 (38.7) 110 (30.2) -1.9 31.8 0.69
HDL = high density lipoprotein; LDL = low density lipoprotein; SD = standard deviationAIDS Research and Therapy 2009, 6:29 http://www.aidsrestherapy.com/content/6/1/29
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all parameters of bowel habits assessed. Among subjects
reporting a change in their bowel habit pattern, improve-
ments were noted in stool consistency (less loose), fre-
quency (decreased), volume (decreased) and the presence
of blood (reduced). Only stool consistency reached the
pre-defined significant α-level of ≤0.05 however. In addi-
tion, aggregate change in bowel habit profile, as assessed
by change in mean BHS-score, was statistically signifi-
cantly improved at week 4, and this was maintained
through week 12 (-0.281, p = 0.002; and -0.227, p = 0.01,
respectively). These changes in GI-tolerability observed
with the tablet are consistent with the observed preference
of the tablet to the SGC. Furthermore, when interpreted in
the context of a cohort of stable patients already tolerant
of the SGC, the observed improvement in GI-tolerability
is notable. For HIV-infected patient naïve to LPV/r, the
tablet formulation might exhibit a superior GI-tolerance
profile than has been reported previously for this drug.
Corroborative findings of improved GI-tolerability and
preference of the tablet over the SGC reported in a
number of recent small cohort studies lend additional
support to this speculation [10-12]. It should be noted
however that difference in GI-tolerance between the SGC
and the tablet formulation was not observed in the larger
M05-730 [7]. A possible explanation for this difference
could be in the design of the two studies. Whereas the cur-
rent study employed instruments specific for capturing
details of GI symptoms, in the M05-730, this information
may have been obtained as part of the general adverse
event reporting.
Additionally, we observed a linear inverse relationship
between overall tolerability of the LPV/r tablet and bowel
habit pattern. For every unit reduction in BHS-score from
baseline to week 4, the GCI tolerability score at week 4
improves by an average of 1.2 points (slope = -1.2, p =
0.02). Although improvement in overall tolerability with
the LPV/r tablet, as assessed by the GCI-score, might be
attributable to multiple factors; this correlation between
the GCI and BHS scores does suggest that it may, in part,
be related to better GI-tolerability with this formulation.
However, the strength of this relationship seemed to wane
by week 12 (slope = -0.95, p = 0.11).
Because the study population consisted of patients who
were clinically stable on a LPV/r-based antiretroviral ther-
apy, we did not expect an appreciable change in QoL. It
was therefore reassuring that following the formulation
switch, all measures of QoL (MOS-HIV health survey
(PHS and MHS), ASDM, and CES-D instruments)
assessed in this study were stable. In addition, contrary to
our expectation, mean reductions in total cholesterol of
9.20 mg/dL (p = 0.02), in triglycerides of 33 mg/dL (p =
0.04), and in HDL of 4.50 mg/dL (p = 0.01) unrelated to
lipid-lowering therapy, were observed at week 12. The rea-
son for this observed lipid lowering effect is unclear and
deserves further evaluation in larger cohorts.
Finally, the findings of this study should be interpreted in
the context of a pilot, single arm study with a sample size
of 74 subjects. Nevertheless, it is reassuring that similar
observations regarding the preference and tolerability of
the LPV/r tablet over the SGC have been reported in small,
unpublished cohorts [10-12]. Our findings are also lim-
ited by the fact that for 66% of the subjects, baseline infor-
mation was recalled (within 8 weeks) since they had
already been switched from the SGC to the tablet formu-
lation prior to study entry. Given these limitations, our
findings suggest that the LPV/r tablet is well tolerated in
HIV-infected subjects, with appreciable improvement in
GI-tolerance profile, stable QoL, and a resultant prefer-
ence of this formulation of LPV/r over the SGC. The unex-
pected change in plasma lipid profile observed with this
formulation deserves further evaluation in a larger com-
parative study.
Conclusions
LPV/r-tablet was well tolerated and preferred to the SGC
in HIV infected subjects, with stable QoL and appreciable
improvement in GI-tolerability. The unexpected changes
in lipid profile deserve further evaluation.
Methods
Study Population and Design
This was a prospective, single arm, cohort study that
enrolled clinically stable HIV-infected subjects, age ≥18
years, receiving LPV/r-based antiretroviral therapy. Sub-
jects were enrolled prior to, or within eight weeks of, the
SGC to tablet formulation switch. There were no CD4 T-
cell counts or HIV RNA restrictions. Subjects were
excluded if they were pregnant, or breastfeeding. All sub-
jects were recruited from the Grady Health System Infec-
tious Diseases Program (IDP) Clinic in Atlanta, and
provided written informed consent before undergoing
any study procedures. This study was designed according
to the ethical guidelines for human studies and approved
by the Emory University Institutional Review Board and
Grady Health System Research Oversight Committee.
Intervention
At baseline, demographic and clinical laboratory data
including fasting lipid profile, plasma HIV-1 RNA level,
and CD4+ T-cell counts were obtained. QoL was assessed
by MOS HIV Health Survey, and Augmented Symptom
Distress Module (ASDM) questionnaire. As the target
population consisted of clinically stable individuals on
therapy, severe GI symptoms were not anticipated. Base-
line GI-tolerance profile was assessed by measuring
changes in bowel habit pattern using the Bowel Habit Sur-
vey (BHS), which evaluated the frequency, consistency,AIDS Research and Therapy 2009, 6:29 http://www.aidsrestherapy.com/content/6/1/29
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volume, and the presence or absence of blood in stool.
Subjects' LPV/r SGC were switched to an equivalent dose
of the tablet formulation. For subjects who had switched
prior to study entry, clinical laboratory tests obtained just
prior to the switch were documented as pre-switch labora-
tory values, and baseline questionnaire information was
recalled. During subsequent visits at week 4 and week 12
post-enrollment, QoL questionnaire and BHS were re-
administered. In addition, Therapy Preference Question-
naire, Medication Satisfaction Survey (MSS), and Global
Condition Improvement (GCI) questionnaire were
administered. Clinical laboratory tests (fasting lipid pro-
file, HIV-RNA PCR, and CD4+ T-cell counts) were
obtained at the week 12 visit.
Statistical Analysis
Outcomes of interest were mean changes from baseline or
absolute values at week 12 of medication preference and
satisfaction assessment, GCI tolerability-scores, GI-tolera-
bility assessed by the BHS-score, QoL-score, and fasting
lipid profile. Questionnaires were scored as follows:
The Medication Satisfaction Survey (MSS) included a set of
questions on how subjects' medications affected their
"normal life", made them "feel sick", or made them "feel
about their fight against HIV infection". Responses to
these questions were ranked on a 5-point Likert scale. The
MSS score ranges from 0 - 12 and is a sum of items on the
survey. The score was 0 for someone who answered "all of
the time" for all questions, and 12 for someone who
answered "none of the time" for all of the questions.
Higher numbers represent better satisfaction.
The Therapy Preference Questionnaire
There was no "scoring" of this questionnaire because it
consists of one question that assessed subjects' preference
with regard to formulation type. Proportion of subjects
that preferred one or the other formulation were calcu-
lated and compared.
The Global Condition Improvement (GCI) questionnaire
assessed medication tolerability in terms of whether sub-
jects felt worse or better after the formulation switch, and
to what extent did their condition changed. The GCI was
scored by assigning a value of 0 if the response was "about
the same" (felt neither worse nor better). If the response
to the initial question was "worse", a negative value was
assigned based on the response to the follow-up question.
If the response to the initial question was "better", a posi-
tive value was assigned based on the response to the fol-
low-up question. The final variable has a range of -7 to +7,
with higher positive numbers representing better tolera-
bility.
The MOS-HIV Health Survey contains 35 items that cover
11 dimensions of health including physical functioning,
pain, social functioning, emotional well-being, energy/
fatigue, overall QoL, and health transition. Patient
responses were scored according to the published scoring
algorithm, which ranges from 0 to 100, with higher scores
indicating better health and well-being [13,14]. Mental
Health Summary (MHS) and Physical Health Summary
(PHS)  scores were calculated from the MOS-HIV scale
using a method that transforms the scores to a standard-
ized scale with a mean of 50 and a standard deviation of
10 for that particular population. Mean MHS and PHS
scores above or below the population mean indicated bet-
ter or worse health-related QoL, respectively.
The Augmented Symptoms Distress Module (ASDM) is a
measurement of the presence of common symptoms
related to HIV infection, and the extent to which they
cause distress to the patient. The ASDM included 22 items
that were scored on a scale from 0 to 4, a higher score
reflecting the presence of more symptoms and/or a greater
degree of symptom-related distress [14].
The Center for Epidemiological Studies-Depression (CES-D)
instrument is a depression questionnaire consisting of 20
items with 1-week patient recall [14,15]. Components of
the questionnaire include depressed mood, feelings of
guilt and worthlessness, feelings of hopelessness, loss of
appetite, and sleep disturbance. Possible scores range
from 0 to 60 with a higher score indicating more symp-
toms and lower QoL. In the original version of this scor-
ing system four items were worded in the positive
direction to break set tendencies in responses. However,
for the purposes of this study these questions were
reversed so that all questions represented the same direc-
tion of QoL.
The Bowel Habit Survey (BHS) assessed stool consistency
(solid = 1, loose = 3, watery = 5), volume (small = 1, mod-
erate = 3, large = 5), presence of blood (no = 1, yes = 5),
and frequency (1 - 5). For example, a subject with baseline
responses of: solid, moderate, no blood, and frequency of
"2" would have a score of: (1 + 3 + 1 + 2)/4 = 1.75 for their
baseline BHS score. Therefore the scale has a minimum of
1 (best BHS outcome) and a maximum of 5 (worst BHS
outcome). Subjects' change in stool consistency, volume,
presence of blood, and frequency was compared.
Analytic approach
Baseline characteristics were summarized by descriptive
statistics. Changes in the various covariates from baseline
to week 4 or week 12 were tested using a paired t-test for
continuous outcomes. Proportions were tested using a
chi-square test. Additionally, the proportion of subjects
that had an improvement in stool consistency, volume,
presence of blood, and frequency was also compared. A
linear regression was also performed to examine the rela-Publish with BioMed Central    and   every 
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tionship between change in GCI scores and change in BHS
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